A business focused overview of the new Egyptian pricing framework for human medicinal products

1. Innovator Pricing: From Reference Price to Value

For innovator products, the starting point remains External Reference Pricing (ERP). The price is based on the lowest ex-factory price of the product in the applicable reference countries where it is marketed, with distributor and pharmacist margins subsequently added. However, Decree 480 goes beyond international reference pricing alone.

The pricing pathway changes according to the reference ex-factory price:

· Below EGP 50,000: External Reference Pricing

· EGP 50,000–500,000: Value-Based Pricing

· Above EGP 500,000: International reference pricing with closer price re-evaluation

Value-Based Pricing

For products with a reference ex-factory price between EGP 50,000 and EGP 500,000, Value-Based Pricing becomes relevant. If an innovative or targeted therapy for the same therapeutic purpose is already registered and priced in Egypt, and a direct or indirect clinical comparison is available, an Economic Evaluation is performed. If no suitable innovative or targeted comparator is registered and priced locally, the product may instead be assessed through Multi-Criteria Decision Analysis (MCDA).

In simple terms, the pricing question is no longer only:

“What is the product priced at globally?”

It also becomes:

“What therapeutic value does this product provide, and does that value justify its price?”

Business Impact

Companies need to prepare more than international price references.

A strong pricing strategy may increasingly require:

· Clinical evidence

· A clear value story

· Health-economic evidence

· Global pricing strategy

2. Very High-Cost Innovators

For innovator products where the lowest reference ex-factory price exceeds EGP 500,000, pricing is based on the lowest ex-factory price in countries where the product is marketed.

Importantly, these countries do not necessarily have to be among the formal reference-country list.

These products are also subject to closer re-evaluation:

· First re-evaluation after 9 months

· Further re-evaluation every 6 months

· Up to 3 re-evaluations

Business Impact

High-cost innovation may receive greater flexibility at initial pricing, but this comes with closer post-launch price monitoring. Companies therefore need to consider from the beginning:

Launch Price + Global Price Evolution + Re-evaluation Strategy

3. Market Entry Timing Can Affect Innovator Pricing

If an innovator is submitted for pricing after a generic or biosimilar is already registered and marketed in Egypt:

· The innovator may be priced 35% above the generic price

·  The innovator may be priced 20% above the biosimilar price

The competitive environment therefore becomes part of the pricing strategy. When three generics or biosimilars are marketed and available in quantities sufficient to meet local market needs, the price of an innovator priced for the first time under this Decree may be reduced:

· By 20%, or

· To the lowest market price of the innovator in the reference countries,

whichever is lower. However, the innovator price should not fall below the highest-priced generic or biosimilar marketed in Egypt.

Business Impact

Timing of market entry matters.

The launch sequence of the innovator and its competitors can directly affect future pricing.

4. Localization Incentive

An important exception applies to imported innovator products that are fully localized and manufactured in Egypt. The price-reduction rule linked to the presence of three generics or biosimilars does not apply for at least five years from the first marketing of the locally manufactured packs.

Business Impact

Localization is no longer only a manufacturing decision.

It can also become part of:

Pricing Strategy + Market Access Strategy + Investment Strategy

5. Generic and Biosimilar Pricing: Timing Is Pricing

For generics and biosimilars, Decree 480 links pricing to several factors:

Market Entry Order + Innovator Price + International Price + Existing Competition + Cost Structure + Market Share

This means companies should understand from the beginning:

· How early can we enter the market?

· What price position can we achieve?

· What does our cost structure allow?

· Who is already in the market?

· What happens to our price if we enter later?

When no generic is yet marketed, an initial indicative price of 65% of the innovator price may be used to proceed with registration.

At market readiness, pricing is reassessed according to market-entry order:

· 1st generic: 70% of innovator price

· 2nd and 3rd generics: 65%

· 4th and 5th generics: 60%

· 6th generic onward: 50%

For biosimilars, the initial indicative price is 75% of the innovator price.

At market readiness:

· 1st biosimilar: 80% of innovator price

· 2nd and 3rd biosimilars: 75%

· 4th and 5th biosimilars: 70%

· 6th biosimilar onward: 60%

Imported biosimilars originating from non-reference registration countries are subject to an additional 5% reduction.

The price of an imported generic or biosimilar should not exceed its price in:

· The country of origin, or Any applicable reference pricing country.

For generics, 50% of the innovator price becomes an important benchmark.

For biosimilars, the corresponding benchmark is 60% of the innovator price.

Business Impact

The first biosimilar entering the market may achieve a stronger price position than later entrants.

Again, speed to market becomes part of the pricing strategy. Being early to market can provide a direct pricing advantage. Registration speed, launch readiness and pricing strategy should therefore be planned together.

6. Repricing: Pricing Now Responds to the Economy

One of the most important changes in Decree 480 is the introduction of a structured mechanism for reviewing the prices of products already marketed in Egypt.

The economic formula is weighted as follows:

· Exchange Rate: 60%

· Inflation: 30%

· Interest Rate: 10%

Price Change = 60% FX Change + 30% Inflation + 10% Interest Rate Change

The calculation is performed every six months, although EDA may apply it earlier in exceptional economic circumstances.

A price increase is not automatic.

If the formula indicates an increase, the Marketing Authorization Holder may request a price adjustment provided that:

· The calculated increase is at least 10%

· The economic changes have continued for at least 45 days

Companies may also request a review of the price of selected marketed products.

At least six months should have passed since the most recent Pricing Notification.

The pricing review may consider:

· Product Cost List

· Prices in reference countries

· Generic or biosimilar prices

· Therapeutic alternatives

· Economic evaluation studies

Business Impact

Companies do not always need to wait for a broad macroeconomic review.

If the economics of a specific product change, an evidence-based repricing case may be built.

7. EDA Can Reassess Prices

EDA retains the right to reconsider product prices and potentially reduce them based on pricing-study data, even if the current Pricing Notification is still valid.

The reduced price applies to batches manufactured or imported after issuance of the new pricing notification.

The reduced innovator price is also considered when pricing related generics or biosimilars.

Business Impact

A change in the innovator price may create a cascade effect across an entire therapeutic category.

8. Distributor and Pharmacist Margins

The Decree also defines different distributor and pharmacist margins according to product type and price.

For locally manufactured products included in the Essential Medicines List.

If a company switches a product from local manufacturing to importation as a fully finished product, distributor and pharmacist margins continue to follow the percentages applicable to locally manufactured products.

The importing company bears the difference in the applicable margin.

Business Impact

Companies should not look only at the Public Price.

The full commercial equation is:

Public Price → Distributor Margin → Pharmacy Margin → Company Net Revenue

Channel economics therefore need to be included in the pricing and profitability model.

A Make-or-Buy or manufacturing-model decision can directly affect:

Landed Cost + Company Margin + Final Profitability

9. Pricing Notification Validity and Pricing Appeals

Pricing Notifications now have defined validity periods.

For products priced up to EGP 50,000:

·  Validity: 5 years

·  Repricing submission: 3 months before expiry

For products priced above EGP 50,000:

·  Validity: 2 years

·  Repricing submission: 2 months before expiry

The previous price remains applicable until EDA changes it.

Products above EGP 500,000 also remain subject to the specific re-evaluation periods applicable to very high-cost products.

A company may appeal the price determined by EDA within three months from the date it is notified of the price.

If an appeal is submitted within this period, EDA issues its decision within two months from the date of submission.

10. Combination Products

If a combination product contains more than one active ingredient, and those active ingredients are already registered separately, the price of the combination product should not exceed the combined prices of the individually registered products.

Combination Product Price ≤ Sum of Individual Component Prices

Business Impact

Pricing feasibility should be considered early when developing or registering fixed-dose combinations.

What Does Decree 480/2026 Really Change?

The biggest change is not simply a new set of percentages.

Decree 480 makes pricing part of the full product lifecycle:

Global Price Strategy → Clinical Value → Market Entry → Competition → Cost → Localization → Economic Changes → Repricing → Channel Margins → Line Extensions → Appeals



Companies therefore need more than a strong Pricing Team. They need an Integrated Pricing Strategy bringing together:

Regulatory Affairs + Market Access + Medical + Finance + Commercial + Supply Chain

Pricing does not start at submission and it does not end at approval.

It becomes a continuous business and regulatory strategy across the entire product lifecycle.